Recorded fact · drug.label_indication
drug.label_indication for mepolizumab|eosinophilic-granulomatosis-with-polyangiitis
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 280aee3a resolves to.
The record
| Fact id | 280aee3a49bff72a235d1c3b |
|---|---|
| Entity | drug: mepolizumab|eosinophilic-granulomatosis-with-polyangiitis |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20250806 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Shown with dashes as hyphens. SHA-256 of the exact stored quote: ded1f900868bde2bf3954f5f3476488f3536f011ead0a1ac48942a5215de33ad.
The value
{
"ingredient": "Mepolizumab",
"conditionId": "eosinophilic-granulomatosis-with-polyangiitis",
"conditionName": "Eosinophilic granulomatosis with polyangiitis",
"matchedAlias": "eosinophilic granulomatosis with polyangiitis",
"context": "indication",
"brand": "Nucala",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "fefb887c-e4ac-431e-8893-e9d1a5a63fea",
"labelEffectiveTime": "20250806",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 880e8fa16e7a83fdadc8a0fed76a5f676e5fce52dd8ca70bc16bef79fc40d985.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.